© 2002 by European Society of Cardiology
Copyright © 2001, European Society of Cardiology
Old and new tools to dissect calcineurin's role in pressure-overload cardiac hypertrophy
Department of Internal Medicine/Hypertension Division, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390-8586, USA
wzhang{at}mednet.swmed.edu
* Tel.: +1-214-648-7944; fax: +1-214-648-7902
In the last several years, a number of experiments have implicated a pivotal role of the calcium/calmodulin-calcineurin dependent pathway as a final common signaling mechanism by which diverse hypertrophic stimuli converge to mediate hypertrophic responses in cardiomyocytes. Calcineurin inhibitors, i.e. cyclosporine A (CsA) and FK506, can interrupt the pathway, thereby preventing cardiac hypertrophy. The data that convincingly support this novel hypothesis were derived either from in vitro studies in cultured cardiomyocytes or from in vivo studies in transgenic mice. However, when the hypothesis was tested in clinically relevant animal models of cardiac hypertrophy, controversial results and conclusions emerged. In conventional models of cardiac hypertrophy, two questions remain to be answered: (1) whether calcineurin is activated in hypertrophied cardiac muscle, and (2) whether calcineurin inhibitors prevent cardiac hypertrophy. In addition, clinical observations have revealed that calcineurin inhibitors appear to exert pro-hypertrophic effects in organ transplant recipients. The controversies suggest that current calcineurin inhibitors are blunt tools for testing the hypothesis in pressure-overload hypertrophy in vivo, because there are so many confounding effects that are associated with systemic administration of the drugs. As such, new genetic approaches may overcome some of the problems associated with pharmacological inhibitors. This invited review will focus on the controversies surrounding the ability of calcineurin inhibition to prevent conventional (pressure-overload) cardiac hypertrophy and the new genetic approaches to address the question.
KEYWORDS ACE inhibitors; Gene expression; Hypertension; Hypertrophy
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Davis, M. V. Westfall, D. Townsend, M. Blankinship, T. J. Herron, G. Guerrero-Serna, W. Wang, E. Devaney, and J. M. Metzger Designing Heart Performance by Gene Transfer Physiol Rev, October 1, 2008; 88(4): 1567 - 1651. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. MacDonnell, H. Kubo, D. M. Harris, X. Chen, R. Berretta, M. F. Barbe, S. Kolwicz, P. O. Reger, A. Eckhart, B. F. Renna, et al. Calcineurin inhibition normalizes beta-adrenergic responsiveness in the spontaneously hypertensive rat Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H3122 - H3129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Stupka, D. R. Plant, J. D. Schertzer, T. M. Emerson, R. Bassel-Duby, E. N. Olson, and G. S. Lynch Activated calcineurin ameliorates contraction-induced injury to skeletal muscles of mdx dystrophic mice J. Physiol., September 1, 2006; 575(2): 645 - 656. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Burkard, J. Becher, C. Heindl, L. Neyses, K. Schuh, and O. Ritter Targeted Proteolysis Sustains Calcineurin Activation Circulation, March 1, 2005; 111(8): 1045 - 1053. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Selvetella, E. Hirsch, A. Notte, G. Tarone, and G. Lembo Adaptive and maladaptive hypertrophic pathways: points of convergence and divergence Cardiovasc Res, August 15, 2004; 63(3): 373 - 380. [Abstract] [Full Text] [PDF]
|
|